Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Utilization of CRISPR Interference To Validate MmpL3 as a Drug Target in Mycobacterium tuberculosis.

Literature DB >> 31160289

Utilization of CRISPR Interference To Validate MmpL3 as a Drug Target in Mycobacterium tuberculosis.

Matthew B McNeil^1,2, Gregory M Cook^3,2.

Abstract

There is an urgent need for novel therapeutics to treat Mycobacterium tuberculosis infections. Genetic strategies for validating novel targets are available, yet their time-consuming nature limits their utility. Here, using MmpL3 as a model target, we report on the application of mycobacterial CRISPR interference for the rapid validation of target essentiality and compound mode of action. This strategy has the potential to rapidly accelerate tuberculosis drug discovery.

Entities: Disease Species

Keywords: CRISPRi; molecular genetics; mycobacteria

Year: 2019 PMID： 31160289 PMCID： PMC6658742 DOI： 10.1128/AAC.00629-19

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

16 in total

1. Susceptibility testing: accurate and reproducible minimum inhibitory concentration (MIC) and non-inhibitory concentration (NIC) values.

Authors: R J Lambert; J Pearson
Journal: J Appl Microbiol Date: 2000-05 Impact factor: 3.772

2. φ(2)GFP10, a high-intensity fluorophage, enables detection and rapid drug susceptibility testing of Mycobacterium tuberculosis directly from sputum samples.

Authors: Paras Jain; Travis E Hartman; Nell Eisenberg; Max R O'Donnell; Jordan Kriakov; Karnishree Govender; Mantha Makume; David S Thaler; Graham F Hatfull; A Willem Sturm; Michelle H Larsen; Preshnie Moodley; William R Jacobs
Journal: J Clin Microbiol Date: 2012-01-25 Impact factor: 5.948

3. Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.

Authors: Jozef Stec; Oluseye K Onajole; Shichun Lun; Haidan Guo; Benjamin Merenbloom; Giulio Vistoli; William R Bishai; Alan P Kozikowski
Journal: J Med Chem Date: 2016-06-22 Impact factor: 7.446

4. Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target.

Authors: Bing Zhang; Jun Li; Xiaolin Yang; Lijie Wu; Jia Zhang; Yang Yang; Yao Zhao; Lu Zhang; Xiuna Yang; Xiaobao Yang; Xi Cheng; Zhijie Liu; Biao Jiang; Hualiang Jiang; Luke W Guddat; Haitao Yang; Zihe Rao
Journal: Cell Date: 2019-01-24 Impact factor: 41.582

5. MmpL3 is the flippase for mycolic acids in mycobacteria.

Authors: Zhujun Xu; Vladimir A Meshcheryakov; Giovanna Poce; Shu-Sin Chng
Journal: Proc Natl Acad Sci U S A Date: 2017-07-11 Impact factor: 11.205

6. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis.

Authors: Wei Li; Ashutosh Upadhyay; Fabio L Fontes; E Jeffrey North; Yuehong Wang; Debbie C Crans; Anna E Grzegorzewicz; Victoria Jones; Scott G Franzblau; Richard E Lee; Dean C Crick; Mary Jackson
Journal: Antimicrob Agents Chemother Date: 2014-08-18 Impact factor: 5.191

7. Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.

Authors: Wei Li; Andrés Obregón-Henao; Joshua B Wallach; E Jeffrey North; Richard E Lee; Mercedes Gonzalez-Juarrero; Dirk Schnappinger; Mary Jackson
Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.191

8. Essentiality of mmpL3 and impact of its silencing on Mycobacterium tuberculosis gene expression.

Authors: Giulia Degiacomi; Andrej Benjak; Jan Madacki; Francesca Boldrin; Roberta Provvedi; Giorgio Palù; Jana Kordulakova; Stewart T Cole; Riccardo Manganelli
Journal: Sci Rep Date: 2017-02-27 Impact factor: 4.379

9. Synergistic Interactions of MmpL3 Inhibitors with Antitubercular Compounds In Vitro.

Authors: Wei Li; Andrea Sanchez-Hidalgo; Victoria Jones; Vinicius Calado Nogueira de Moura; E Jeffrey North; Mary Jackson
Journal: Antimicrob Agents Chemother Date: 2017-03-24 Impact factor: 5.191

Review 10. The application of tetracyclineregulated gene expression systems in the validation of novel drug targets in Mycobacterium tuberculosis.

Authors: Joanna C Evans; Valerie Mizrahi
Journal: Front Microbiol Date: 2015-08-04 Impact factor: 5.640

16 in total

1. Transcriptional Inhibition of the F₁F₀-Type ATP Synthase Has Bactericidal Consequences on the Viability of Mycobacteria.

Authors: Matthew B McNeil; Heath W K Ryburn; Liam K Harold; Justin F Tirados; Gregory M Cook
Journal: Antimicrob Agents Chemother Date: 2020-07-22 Impact factor: 5.191

Review 2. CRISPR-Based Approaches for Gene Regulation in Non-Model Bacteria.

Authors: Stephanie N Call; Lauren B Andrews
Journal: Front Genome Ed Date: 2022-06-23

Review 3. Structural and Functional Diversity of Resistance-Nodulation-Cell Division Transporters.

Authors: Philip A Klenotic; Mitchell A Moseng; Christopher E Morgan; Edward W Yu
Journal: Chem Rev Date: 2020-11-19 Impact factor: 60.622

Review 4. Mycobacterium tuberculosis Shikimate Pathway Enzymes as Targets for the Rational Design of Anti-Tuberculosis Drugs.

Authors: José E S Nunes; Mario A Duque; Talita F de Freitas; Luiza Galina; Luis F S M Timmers; Cristiano V Bizarro; Pablo Machado; Luiz A Basso; Rodrigo G Ducati
Journal: Molecules Date: 2020-03-11 Impact factor: 4.411